HydroLock™ ADC Platform
Bispecific or Biparatopic ADC to Address Tumor Heterogeneity
1. Stabler link tech enables low free toxic payload in the circulation, and thus wider therapeutic window (HydroLock™).
2. Dual targeting improves ADC delivery, efficcy and overcomes tumor heterogeniety.